外泌体 miR-221 靶向 DNM3 促进胶质瘤进展并诱导替莫唑胺耐药
本研究通过临床样本 qPCR 检测 miR-221 表达,并在 SHG-44 细胞中观察抗 miR-221 或 U87MG 来源外泌体对细胞活力、迁移及替莫唑胺耐药的影响,采用双荧光素酶报告实验等验证 DNM3 为 miR-221 靶点、RELA 调控 miR-221 表达;组织与外泌体 miR-221 表达均随胶质瘤级别升高,作者认为 RELA/miR-221 轴可作为胶质瘤诊断与治疗靶点。
要点
- 组织水平与外泌体 miR-221 表达均随胶质瘤级别升高。
- SHG-44 细胞中下调 miR-221 抑制增殖、迁移和替莫唑胺耐药,U87MG 来源外泌体呈促瘤效应。
- DNM3 为 miR-221 靶点,RELA 诱导 miR-221 表达,RELA/miR-221 轴被作者视为诊治靶点。
核心结论
- 作者认为胶质瘤中升高的 miR-221 表达是胶质瘤的生物标志物。
- DNM3 是 miR-221 的靶点,RELA 调控 miR-221 表达。
- 作者认为 RELA/miR-221 轴是胶质瘤诊断和治疗的靶点。
研究设计与样本
- 研究采用临床样本以定量逆转录聚合酶链反应(qPCR)分析 miR-221 表达。
- SHG-44 细胞经抗 miR-221 或 U87MG 来源外泌体处理,监测细胞活力、迁移和替莫唑胺耐药变化。
- 采用生物信息学方法识别 miR-221 的靶点。
- 以双荧光素酶报告实验、Spearman 相关分析和蛋白免疫印迹研究 miR-221 与其靶点 DNM3 基因的相互作用。
- 将表达 RELA 的载体或 shRNA 导入 SHG-44 细胞,监测其对 miR-221 表达的影响。
主要发现
- 组织水平和外泌体 miR-221 表达均随胶质瘤级别升高。
- SHG-44 细胞中下调 miR-221 表达抑制细胞增殖、迁移和替莫唑胺耐药。
- SHG-44 细胞与 U87MG 来源外泌体共孵育产生促瘤效应。
- DNM3 基因是 miR-221 的靶点。
- RELA 诱导 miR-221 表达。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
MicroRNA is an important regulator of glioblastoma. This study aims at validating microRNA-221 (miR-221) as a biomarker for glioblastoma, and understanding how miR-221 regulates glioblastoma progression. Using clinical samples, miR-221 expression was analyzed by quantitative reverse-transcriptase PCR (qPCR). SHG-44 cells were treated with anti-miR-221 or U87MG-derived exosomes followed by monitoring changes in cell viability, migration and temozolomide (TMZ) resistance. Bioinformatics approach was used to identify targets of miR-221. The interaction between miR-221 and its target, DNM3 gene, was studied with dual-luciferase reporter assay, Spearman's correlation analysis, and western blotting. To verify that RELA regulates miR-221 expression, RELA-expressing vector or shRNA was introduced into SHG-44 cells and its effect on miR-221 expression was monitored. Both tissue-level and exosomal miR-221 expression increased with glioma grades. In SHG-44 cells, downregulating miR-221 expression inhibited cell proliferation, migration, and TMZ resistance, whereas incubation with U87MG-derived exosomes exerted tumor-promoting effects. DNM3 gene is a target of miR-221. RELA induced miR-221 expression. In glioma, elevated miR-221 expression is a biomarker for glioma. DNM3 is a target of miR-221 and RELA regulates miR-221 expression. The RELA/miR-221 axis is a target for glioma diagnosis and therapy.
引用
- Yang JK, Yang JP, Tong J, et al. Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma. J Neurooncol. 2016. PMID: 27837435. doi:10.1007/s11060-016-2308-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。